BioSpace News Archive

Preclinical study identifies vulnerability in orphan cancers with SMARCB1 mutations, spurs launch of Phase II clinical trial

In June 2018, Kilroy said it plans to develop, over multiple phases, a state-of-the-art laboratory and office complex that will eventually encompass 11 buildings spread across a nearly 40-acre waterfront site in the Bay Area.

Karolinska Development’s portfolio company OssDsign announces today the closing of a private placement of SEK 64 million.

Researchers in the School of Pharmacy at the University of Nottingham have been using Dolomite Microfluidic’s chips to enhance their work on drug encapsulation and therapeutic delivery.

Analyst David Bautz, PhD of Zack’s Investment Research, Inc. updated coverage on Soligenix, Inc. on February 12, 2019. For more information, please visit SCR.Zacks.com.

Darzalex (daratumumab) for intravenous infusion is approved in the U.S. in combination with bortezomib, melphalan and prednisone for patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant.

Recipharm, the contract development and manufacturing organisation, has appointed a new director of business management for the USA and Canada to accelerate growth in the region.

Estimated enterprise value of EUR 160 million compared to current EV of EUR 121 million

Request and task management software increases operational efficiency of biopharma R&D organizations

Auris Medical Holding AG announced its receipt of notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company did not meet Nasdaq’s January 28, 2019 deadline to regain compliance with Nasdaq Listing Rule 5550(a)(2) due to the bid price per share for its common shares remaining below $1.00.